Avasa has secured NZD $4.75 million in funding, led by Movac, to advance the Avasa Coupler, a transformative device for reconstructive microsurgery.
Target Information
Avasa is a cutting-edge medical device startup based in New Zealand, founded by clinician-bioengineer Dr. Nandoun Abeysekera. The company specializes in developing innovative solutions for reconstructive microsurgery, specifically addressing the need for effective micro-artery reconnections. Their flagship product, the Avasa Coupler, is designed to enable safe, rapid, and standardized reconnections of micro-arteries, significantly improving upon the complex and time-consuming traditional methods.
With the completion of seven years of rigorous research and development, Avasa has reached a significant milestone by finalizing the design of the Coupler and producing pre-production units that have demonstrated a 100% success rate in chronic animal studies. Feedback from over 100 microsurgeons indicates a strong clinical demand for this solution, further validating its importance in the field of microsurgery.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The healthcare sector in New Zealand has been experiencing substantial growth, particularly in the advanced medical technology area. The country has established itself as a hub for innovation in healthcare s
Similar Deals
Pacific Channel → Upstream Medical Technologies
2023
Movac
invested in
Avasa
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $3M